Study guide
5.3 Genetic Risk Assessment & Family History Counseling
ABFM Family Medicine Certification Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making
1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care
2 Chapter 2: Healthcare Systems, Practice Management & Quality
2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination
3 Chapter 3: Ethics, Law, Biostatistics & Health Equity
3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism
4 Chapter 4: Lifestyle Counseling & Behavior Change
4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling
5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention
5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling
6 Chapter 6: Routine Adult Immunizations
6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise
7 Chapter 7: Pediatric Health Maintenance & Surveillance
7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride
8 Chapter 8: Behavioral Health & Safety Screening
8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling
9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic
9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening
10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic
10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling
11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate
11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making
12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception
12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C
13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care
13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam
14 Chapter 14: Emergent Cardiovascular Conditions
14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies
15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises
15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management
16 Chapter 16: Vascular & Thromboembolic Emergencies
16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion
17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness
17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion
18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies
18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies
19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies
19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice
20 Chapter 20: Acute Pulmonary & Airway Emergencies
20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction
21 Chapter 21: Acute Traumatic Injuries & Wound Care
21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites
22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies
22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises
23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies
23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection
24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies
24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis
25 Chapter 25: Hematologic, Urologic & Dental Emergencies
25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma
26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies
26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia
27 Chapter 27: Acute Head, Neck & Neurologic Symptoms
27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring
28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms
28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis
29 Chapter 29: Acute Upper Respiratory Tract Infections
29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion
30 Chapter 30: Acute Lower Respiratory Infections & Cough
30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia
31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions
31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation
32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms
32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation
33 Chapter 33: Acute Upper Gastrointestinal Conditions
33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness
34 Chapter 34: Acute Lower Gastrointestinal Conditions
34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani
35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders
35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes
36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders
36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis
37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions
37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation
38 Chapter 38: Acute Infectious Dermatoses
38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum
39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses
39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma
40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries
40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains
41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries
41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes
42 Chapter 42: Acute Ambulatory Fractures & Dislocations
42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation
43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls
43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients
44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain
44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies
45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions
45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction
46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions
46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation
47 Chapter 47: Acute Women's Health & Early Pregnancy Care
47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder
48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination
48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis
49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections
49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses
50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia
50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT
51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases
51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy
52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD
52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria
53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus
53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance
54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases
54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition
55 Chapter 55: Chronic Endocrine Disorders
55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders
56 Chapter 56: Chronic Kidney Disease & Venous Disorders
56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD
57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases
57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy
58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care
58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders
59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders
59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome
60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders
60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care
61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders
61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness
62 Chapter 62: Chronic Psychiatric Disorders
62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder
63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions
63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating
64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation
64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy
65 Chapter 65: Chronic Dermatologic Conditions
65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus
66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care
66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control
67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit
67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit
5.3 Genetic Risk Assessment & Family History Counseling
Key Takeaways Explain This Topic AI
A comprehensive 3-generation pedigree is the foundational genetic screening tool in primary care; clinical red flags prompting formal cancer genetic evaluation include disease onset <50 years, multiple primary malignancies, bilateral tumors, rare cancers, and ≥2 affected first-degree relatives.
The USPSTF recommends (Grade B) that primary care clinicians screen women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer using a validated risk assessment tool (e.g., Tyrer-Cuzick, BRCAPRO, Manchester Scoring); positive screens require genetic counseling and potential BRCA1/2 testing.
Lynch syndrome (HNPCC), caused by germline mutations in DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM), carries a 50–80% lifetime risk of colorectal cancer and 40–60% risk of endometrial cancer; surveillance mandates colonoscopy every 1–2 years beginning at age 20–25.
Familial Adenomatous Polyposis (FAP) is an autosomal dominant APC mutation characterized by hundreds to thousands of adenomatous polyps with near 100% colorectal cancer penetrance by age 40–50; surveillance requires annual flexible sigmoidoscopy or colonoscopy starting at age 10–12.
The Genetic Information Nondiscrimination Act (GINA) prohibits health insurers and employers from discriminating based on genetic test results or family history, but GINA explicitly excludes life insurance, disability insurance, long-term care insurance, and active-duty military personnel.
Last updated: September 2026
Pedigree Construction & Standardized Family History Analysis
A meticulously constructed family pedigree serves as the primary clinical genetic screening instrument in ambulatory family medicine. Systematic collection of family history enables clinicians to stratify patient risk, identify monogenic hereditary syndromes, tailor cancer surveillance protocols, and initiate life-saving cascade genetic testing.
The 3-Generation Pedigree
A comprehensive pedigree must encompass at least three generations of biological relatives:
First-Degree Relatives (FDRs) : Parents, full siblings, and biological children (share 50% of genetic material on average).
Second-Degree Relatives (SDRs) : Grandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings (share 25% of genetic material).
Third-Degree Relatives (TDRs) : First cousins, great-grandparents, and great-grandchildren (share 12.5% of genetic material).
Standardized Pedigree Nomenclature & Symbols
Geometric Symbols : Square = Male; Circle = Female; Diamond = Sex unspecified/unknown.
Status Indicators : Filled / Shaded Symbol = Affected with clinical disease/phenotype; Half-Filled Symbol = Heterozygous carrier of an autosomal recessive gene or X-linked trait; Diagonal Slash = Deceased individual; Arrow pointing to symbol with 'P' = Proband (the index patient presenting for clinical evaluation).
Relationship Lines : Horizontal line connecting a male and female = Mating/relationship; Double horizontal line = Consanguinity (mating between blood relatives, strongly increasing risk of autosomal recessive disorders); Vertical line descending from mating line = Biological offspring (arranged chronologically from left to right by birth order).
Essential Clinical Annotations : For every relative, record current age (or age at death and cause of death), specific cancer or disease diagnoses, exact age at primary diagnosis, tumor anatomical location/laterality, and relevant environmental exposures (e.g., heavy tobacco use).
Red Flags for Hereditary Cancer Syndromes: The "PREDISPOSE" Framework
Clinicians should immediately recognize classic clinical hallmarks of hereditary cancer syndromes:
P - Premature Onset : Cancer diagnosed at an unusually early age (e.g., colorectal, breast, or endometrial cancer diagnosed before age 50).
R - Rare Tumors : Identification of unusual neoplasms (e.g., male breast cancer, medullary thyroid cancer, pheochromocytoma, adrenocortical carcinoma, diffuse gastric cancer, sebaceous adenomas).
E - Excessive Polyposis : Presence of >10 to 20 cumulative adenomatous colorectal polyps.
D - Dual / Multiple Primaries : Synchronous or metachronous primary cancers in a single individual (e.g., bilateral breast cancer; colorectal cancer plus synchronous endometrial cancer).
I - Inherited Pattern : Autosomal dominant transmission pattern across multiple successive generations (vertical transmission affecting males and females alike).
S - Specific Syndromic Clusters : Constellations of biologically linked tumors (e.g., breast-ovarian-pancreatic-prostate clustering; colorectal-endometrial-ovarian-gastric clustering).
P - Pathognomonic Non-Malignant Features : Physical stigmata such as macrocephaly and mucocutaneous trichilemmomas (Cowden syndrome), mucosal melanin pigmentation of the lips and buccal mucosa (Peutz-Jeghers syndrome), or congenital hypertrophy of the retinal pigment epithelium (CHRPE in FAP).
O - Origin / Ancestry : Specific ethnic ancestry associated with founder mutations (e.g., Ashkenazi Jewish ancestry , which carries a 1 in 40 carrier frequency for BRCA1/2 mutations compared to 1 in 400 in the general population).
S - Several Affected Relatives : Two or more first- or second-degree relatives with the same or related tumor types.
E - Exact Histology : High-grade serous ovarian cancer, triple-negative breast cancer, or microsatellite-unstable (MSI-High) colorectal tumors.
- Hereditary Breast & Ovarian Cancer Syndrome (HBOC - BRCA1 & BRCA2)
- Molecular Genetics & Cancer Penetrance
HBOC is an autosomal dominant condition caused by germline loss-of-function mutations in the tumor suppressor genes BRCA1 (chromosome 17q21) or BRCA2 (chromosome 13q12). Both genes encode large nuclear proteins essential for the homologous recombination repair (HRR) pathway that repairs DNA double-strand breaks.
Lifetime Malignancy Risks in Mutation Carriers :
Female Breast Cancer : 60% to 80% lifetime risk (often diagnosed premenopausally; BRCA1 cancers are predominantly triple-negative [estrogen receptor-negative, progesterone receptor-negative, HER2-negative], whereas BRCA2 cancers are frequently hormone receptor-positive).
Ovarian / Fallopian Tube / Primary Peritoneal Cancer : 40% to 50% lifetime risk for BRCA1; 10% to 20% lifetime risk for BRCA2 (predominantly high-grade serous carcinoma arising in the fimbriated end of the fallopian tube).
Male Breast Cancer : ~7% to 8% lifetime risk in BRCA2 carriers (only 1% to 2% in BRCA1).
Prostate Cancer : 20% to 25% lifetime risk in male BRCA2 carriers, characterized by aggressive, high-Gleason score pathology and early metastatic progression.
Pancreatic Adenocarcinoma : 3% to 5% lifetime risk in both BRCA1 and BRCA2.
Cutaneous Melanoma : Significantly elevated relative risk primarily associated with BRCA2 mutations.
USPSTF Grade B Recommendations for BRCA Screening
The U.S. Preventive Services Task Force recommends ( Grade B ) that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer, or who have an ancestry associated with BRCA1/2 gene mutations, using a validated familial risk assessment tool :
Validated Screening Instruments : Ontario Family History Assessment Tool (FHAT), Manchester Scoring System, BRCAPRO, Tyrer-Cuzick (IBIS model) , and the Pedigree Assessment Tool (PAT).
Clinical Workflow :
Women whose screening assessment is positive should receive pre-test genetic counseling conducted by a certified genetic counselor or trained genetics professional.
If indicated following formal counseling and shared decision-making, the patient should undergo targeted or multi-gene panel genetic testing.
If a pathogenic or likely pathogenic variant is identified, cascade genetic testing is offered to all at-risk biological relatives.
USPSTF Grade D Warning : The USPSTF explicitly recommends against routine genetic counseling or testing for women whose personal or family history is not associated with an increased risk for pathogenic BRCA1/2 variants (Grade D recommendation).
Clinical Management of BRCA Mutation Carriers
Intensive Breast Surveillance :
Annual contrast-enhanced breast MRI beginning at age 25 (or 5 to 10 years before the earliest familial breast cancer diagnosis).
Add annual mammography (digital breast tomosynthesis) beginning at age 30 , alternating modalities every 6 months (e.g., breast MRI in January, mammography in July).
Risk-Reducing Bilateral Salpingo-Oophorectomy (RRBSO) :
Recommended at age 35 to 40 for BRCA1 carriers, and age 40 to 45 for BRCA2 carriers (or upon completion of childbearing).
Reduces ovarian/fallopian tube cancer risk by >80% to 90% and reduces all-cause mortality. Board pearl : Routine ovarian cancer screening with transvaginal ultrasound and serum CA-125 is NOT effective, fails to detect early-stage ovarian cancer, and is NOT recommended as a substitute for RRBSO.
Risk-Reducing Bilateral Mastectomy : Reduces invasive breast cancer risk by >90% to 95% .
Male Carrier Protocols : Annual clinical breast examination starting at age 35; annual PSA screening starting at age 40 for BRCA2 carriers.
- Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer / HNPCC)
- Molecular Pathophysiology & DNA Mismatch Repair
Lynch syndrome is the most prevalent hereditary colorectal cancer syndrome, accounting for 3% to 5% of all colorectal carcinomas. It is an autosomal dominant condition caused by germline mutations in one of four DNA Mismatch Repair (MMR) genes:
MLH1 (chromosome 3p21) and MSH2 (chromosome 2p21): Account for ~70% to 80% of all Lynch syndrome mutations (highest penetrance).
MSH6 and PMS2 : Lower penetrance, often presenting with later-onset colorectal or endometrial cancers.
EPCAM Deletions : Deletions in the EPCAM gene (upstream of MSH2) cause epigenetic hypermethylation and transcriptional silencing of the intact MSH2 promoter.
Mechanism : DNA MMR proteins proofread newly synthesized DNA strands and correct base-base mismatches and insertion-deletion loops that occur during replication. Loss of MMR function leads to failure of DNA slippage repair, producing Microsatellite Instability (MSI-High) throughout the genome and accelerating the adenoma-carcinoma sequence from the usual 10 to 15 years down to 2 to 3 years .
Clinical Malignancy Spectrum
Colorectal Cancer (CRC) : 50% to 80% lifetime risk. Characteristically exhibits proximal / right-sided colon predominance (cecum and ascending colon in >70%), poorly differentiated or medullary histology, mucinous features, and abundant tumor-infiltrating lymphocytes.
Endometrial Cancer : 40% to 60% lifetime risk in women. Critical Board Pearl : Endometrial carcinoma is frequently the sentinel cancer in female Lynch carriers, preceding colorectal cancer diagnosis by several years!
Extracolonic Malignancies : Ovarian cancer (10–12%), gastric cancer (5–10%), small bowel adenocarcinoma (duodenum/jejunum, 4–7%), urothelial carcinoma of the renal pelvis and ureter (2–10%), hepatobiliary cancer (2–4%), glioblastoma multiforme (Turcot syndrome variant), and sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas ( Muir-Torre syndrome variant ).
Clinical Diagnostic Criteria: The Amsterdam II Criteria
The classic clinical diagnostic criteria for Lynch syndrome are remembered by the "3-2-1 Rule" :
3 or more relatives with a confirmed Lynch-associated cancer (colorectal, endometrial, small bowel, ureter/renal pelvis).
Involving at least 2 successive generations.
At least 1 affected relative is a first-degree relative of the other two.
At least 1 cancer diagnosed before age 50 .
Familial adenomatous polyposis (FAP) has been excluded.
Tumors verified by pathological review.
Universal Tumor Testing: The Revised Bethesda Guidelines & Modern Standard of Care
While the Revised Bethesda Guidelines historically guided which colorectal tumors should undergo testing, current national guidelines (NCCN, AGA, ASCO) mandate Universal Reflex Screening : ALL newly diagnosed colorectal and endometrial cancers, regardless of patient age or family history, must undergo screening for mismatch repair deficiency .
Reflex Testing Workflow :
Perform Immunohistochemistry (IHC) for the 4 MMR proteins (MLH1, MSH2, MSH6, PMS2) and/or Microsatellite Instability (MSI) testing via PCR on tumor biopsy tissue.
If MSH2, MSH6, or PMS2 proteins are absent on IHC, the patient is directly referred for germline genetic testing.
If MLH1 protein expression is absent , the loss is usually due to sporadic, non-hereditary somatic promoter hypermethylation. To differentiate sporadic cancer from Lynch syndrome, the tumor must undergo testing for the BRAF V600E somatic mutation and MLH1 promoter hypermethylation :
Presence of BRAF V600E mutation OR presence of MLH1 promoter hypermethylation = Sporadic colon cancer (rules out Lynch syndrome; no germline testing required).
Absence of BRAF mutation AND absence of promoter hypermethylation = High suspicion for germline Lynch syndrome ; proceed directly to germline MLH1 sequencing.
Surveillance & Risk-Reduction Protocols for Lynch Syndrome
Colorectal Surveillance : High-quality colonoscopy every 1 to 2 years, beginning at age 20 to 25 (or 2 to 5 years prior to the earliest colorectal cancer diagnosed in the family if diagnosed before age 25). The 1- to 2-year interval is mandatory because the adenoma-carcinoma transition is markedly accelerated.
Gynecologic Surveillance & Prophylaxis : Annual endometrial biopsy and transvaginal ultrasound may be considered starting at age 30 to 35, but has limited diagnostic sensitivity. The definitive recommendation is risk-reducing total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) after completion of childbearing (typically at age 40 to 45).
Upper Gastrointestinal Surveillance : Esophagogastroduodenoscopy (EGD) with baseline biopsy for Helicobacter pylori every 2 to 4 years starting at age 35 to 40.
- Familial Adenomatous Polyposis (FAP) & Polyposis Syndromes
- Molecular Genetics & Phenotypic Manifestations
Familial Adenomatous Polyposis is an autosomal dominant condition with near 100% penetrance, caused by germline mutations in the APC (Adenomatous Polyposis Coli) tumor suppressor gene located on chromosome 5q21. Approximately 25% of cases arise from de novo germline mutations in individuals without a family history.
Classic FAP :
Characterized by the progressive emergence of hundreds to thousands (typically >100 to >1,000) of adenomatous colorectal polyps carpeting the colon and rectum, beginning in adolescence (ages 10 to 15).
Colorectal Cancer Penetrance : If untreated, the progression of polyps to invasive colorectal adenocarcinoma is nearly 100% by age 40 to 50 .
Attenuated FAP (AFAP) :
Characterized by 10 to 99 adenomatous polyps, predominantly located in the right/proximal colon, with a later onset of polyps and delayed colorectal cancer progression (mean age of cancer diagnosis ~55 years).
Extracolonic Manifestations of FAP :
Duodenal & Ampullary Adenomas : Occur in >90% of FAP patients; periampullary duodenal adenocarcinoma is the second leading cause of cancer-related mortality in FAP.
Gastric Fundic Gland Polyps : Present in >50% of patients; low malignant potential.
Desmoid Tumors : Locally aggressive, non-metastasizing monoclonal fibroblastic proliferations arising in the abdominal wall and mesentery in 10% to 15% of patients. Desmoids represent a major cause of post-colectomy morbidity and mortality due to mesenteric vessel encasement and bowel obstruction.
Congenital Hypertrophy of the Retinal Pigment Epithelium (CHRPE) : Bilateral, discrete, pigmented retinal lesions observed on dilated funduscopic exam in >75% of classic FAP patients. CHRPE is asymptomatic and does not cause vision loss, but serves as a pathognomonic clinical marker for FAP in at-risk children.
Osteomas & Soft Tissue Tumors : Benign osteomas of the mandible and skull, epidermoid cysts, and dental abnormalities ( Gardner syndrome ).
Central Nervous System Tumors : Medulloblastomas associated with FAP ( Turcot syndrome ).
Surveillance & Surgical Management Protocols
Colorectal Surveillance : Annual flexible sigmoidoscopy or colonoscopy starting at age 10 to 12 years for classic FAP (or age 18 to 20 for AFAP).
Prophylactic Surgery : Total proctocolectomy with ileal pouch-anal anastomosis (IPAA) , or total abdominal colectomy with ileorectal anastomosis (IRA). Surgery is typically performed in late adolescence or early adulthood (ages 18 to 25) when the polyp burden becomes too dense for endoscopic management or when severe dysplasia arises.
Upper GI Surveillance : Forward- and side-viewing upper endoscopy (EGD) starting at age 25 to 30 to stage duodenal adenomas using the Spigelman staging system.
- Hereditary Cardiomyopathies: Hypertrophic Cardiomyopathy (HCM)
- Molecular Genetics & Pathophysiology
Hypertrophic Cardiomyopathy is an autosomal dominant condition of variable expressivity and incomplete penetrance caused by pathogenic mutations in cardiac sarcomere protein genes. The two most common causative genes are:
MYH7 (beta-myosin heavy chain): Accounts for ~30% to 40% of identified mutations.
MYBPC3 (cardiac myosin-binding protein C): Accounts for ~30% to 40% of identified mutations.
Pathological Hallmark : Disorganized myofibrillar architecture ("myocardial fiber disarray"), marked myocyte hypertrophy, interstitial fibrosis, and asymmetrical left ventricular hypertrophy (most commonly involving the basal anterior interventricular septum). HCM is the single most common cause of sudden cardiac death (SCD) in young athletes under age 35.
Dynamic Auscultation & Hemodynamics (High-Yield Board Concept)
Patients typically present with dynamic Left Ventricular Outflow Tract (LVOT) obstruction caused by septal hypertrophy combined with Systolic Anterior Motion (SAM) of the mitral valve , which makes contact with the septum during midsystole, producing both LVOT obstruction and mitral regurgitation.
Auscultation : Harsh, crescendo-decrescendo systolic ejection murmur heard best at the left lower sternal border (without radiation to the carotid arteries).
Dynamic Bedside Maneuvers :
Maneuvers that INCREASE Murmur Intensity : Maneuvers that decrease left ventricular preload or decrease afterload reduce left ventricular end-diastolic volume, narrowing the LVOT and exacerbating obstruction:
Valsalva Maneuver (strain phase) (decreases venous return / preload).
Sudden Standing from a squatting position (decreases venous return / preload).
Administration of nitrates or dihydropyridine calcium channel blockers (reduces preload/afterload).
Maneuvers that DECREASE Murmur Intensity : Maneuvers that increase left ventricular preload or increase afterload expand the left ventricular chamber, widening the LVOT and relieving obstruction:
Passive Leg Raise (increases venous return / preload).
Squatting (increases venous return and systemic vascular resistance).
Sustained Handgrip (increases systemic vascular resistance / afterload).
Cascade Family Screening Guidelines
All first-degree relatives of an individual diagnosed with HCM should undergo cascade genetic testing if the proband's causative sarcomeric mutation has been identified.
If genetic testing in the family is negative, inconclusive (variant of uncertain significance), or declined, first-degree relatives must undergo serial clinical screening with a 12-lead ECG and transthoracic echocardiogram (TTE) :
Children and adolescents (ages 12 to 18): Every 1 to 2 years .
Adults (age ≥18): Every 3 to 5 years (or immediately if clinical symptoms of chest pain, dyspnea, presyncope, or palpitations emerge).
- Hereditary Hemochromatosis (HH)
- Molecular Genetics & Pathophysiology
Hereditary Hemochromatosis is an autosomal recessive disorder of systemic iron metabolism characterized by uninhibited intestinal iron absorption. More than 85% to 90% of clinical cases in individuals of Northern European descent result from homozygosity for the C282Y mutation (p.Cys282Tyr) in the HFE gene located on chromosome 6p21.3. Less commonly, patients are compound heterozygotes for C282Y / H63D .
Molecular Mechanism : The normal HFE protein binds the transferrin receptor-1 (TfR1) on hepatocytes, signaling circulating iron levels to induce the transcription of hepcidin (the master iron-regulatory hormone). The C282Y mutation prevents HFE cell-surface expression, causing severe deficiency of hepcidin . Without hepcidin, the basolateral iron exporter ferroportin remains constitutively active on duodenal enterocytes and reticuloendothelial macrophages, pumping toxic amounts of iron into the plasma, saturating transferrin, and depositing non-transferrin-bound iron into parenchymal tissues.
Clinical Manifestations: The Classic "Bronze Diabetes" Triad
Clinical symptoms typically emerge between ages 40 and 60 in men; women present on average 10 to 15 years later due to physiological blood and iron losses through menstruation and childbearing.
Liver : Hepatomegaly, elevated transaminases, progressive bridging fibrosis, micronodular cirrhosis, and a 20- to 200-fold increased relative risk of hepatocellular carcinoma (HCC) .
Endocrine: "Bronze Diabetes" : Iron deposition in pancreatic beta cells leads to diabetes mellitus. Deposition in the anterior pituitary gland causes hypogonadotropic hypogonadism , presenting as testicular atrophy, loss of libido, and erectile dysfunction in men, and amenorrhea in women.
Skin : Diffuse slate-gray or hyperpigmented "bronze" skin discoloration resulting from combined melanin and hemosiderin deposition.
Musculoskeletal / Arthropathy : Progressive, chronic degenerative arthropathy characteristically localized to the second and third metacarpophalangeal (MCP) joints and wrists. Plain radiographs demonstrate chondrocalcinosis (calcium pyrophosphate dihydrate / pseudogout), joint space narrowing, and characteristic squared-off bone margins with hook-like osteophytes.
Cardiac : Dilated cardiomyopathy, restrictive cardiomyopathy, conduction system disease, and supraventricular arrhythmias.
Diagnostic Evaluation & Screening Cascade
Initial Biochemical Screening : Fasting Transferrin Saturation (TSAT) and Serum Ferritin .
Fasting TSAT ≥45% (or ≥50% in men) is the single most sensitive initial phenotypic screening test for hemochromatosis.
Serum ferritin reflects total body iron storage. Ferritin is also an acute-phase reactant; therefore, an isolated high ferritin with normal TSAT warrants evaluation for alcohol use, MASLD, infection, or chronic inflammation.
Confirmatory Genetic Testing : If fasting TSAT ≥45% and ferritin is elevated, perform targeted HFE mutation analysis for C282Y and H63D .
Assessing Hepatic Fibrosis & Cirrhosis Risk :
Serum Ferritin >1,000 mcg/L OR elevated serum AST/ALT indicates a high risk for advanced hepatic fibrosis or cirrhosis; these patients mandate hepatic elastography, liver MRI (T2* quantification of hepatic iron content), or a percutaneous liver biopsy to evaluate for cirrhosis and establish the need for lifelong hepatocellular carcinoma surveillance.
Therapeutic Phlebotomy & Clinical Prognosis
Induction Phase : Therapeutic phlebotomy (removal of 1 unit [500 mL] of whole blood , removing ~200 to 250 mg of elemental iron) performed weekly or biweekly .
Target Induction Endpoint : Continue phlebotomy until serum ferritin reaches 50 to 100 mcg/L and TSAT is <50%.
Maintenance Phase : Lifelong maintenance phlebotomy (typically 1 unit every 2 to 4 months) to sustain ferritin between 50 and 100 mcg/L.
High-Yield Clinical Pearl on Phlebotomy Outcomes :
Phlebotomy reverses lethargy, normalizes elevated transaminases, halts the progression of early hepatic fibrosis, reverses dilated cardiomyopathy, and improves glycemic control.
Hemochromatosis Arthropathy (MCP joint pain) typically DOES NOT improve with therapeutic phlebotomy ; joint pain frequently persists or paradoxically worsens despite complete iron depletion, requiring treatment with NSAIDs or joint arthroplasty.
Master Comparative Table of High-Yield Hereditary Syndromes
Syndrome Causative Gene(s) & Inheritance Hallmarks & Associated Malignancies Diagnostic Criteria & Biomarkers Clinical Surveillance & Preventive Interventions
Hereditary Breast & Ovarian Cancer (HBOC) BRCA1, BRCA2 ; Autosomal Dominant Female breast, high-grade serous ovarian/fallopian tube, male breast, pancreatic, aggressive prostate cancer • Validated tool (Tyrer-Cuzick, BRCAPRO, Manchester); • Ashkenazi Jewish ancestry (1 in 40 carrier rate) • Alternating Breast MRI (age 25) and Mammography (age 30) q6m; • Prophylactic RRBSO at age 35–40 (BRCA1) or 40–45 (BRCA2) ; • Male breast exam at age 35; PSA at age 40 (BRCA2)
Lynch Syndrome (HNPCC) MLH1, MSH2, MSH6, PMS2, EPCAM ; Autosomal Dominant Colorectal (right-sided), endometrial (sentinel cancer), ovarian, gastric, small bowel, urothelial, sebaceous neoplasms (Muir-Torre) • Amsterdam II (3-2-1 Rule) ; • Universal tumor testing: IHC for MMR proteins & MSI; • BRAF V600E / MLH1 hypermethylation rules out Lynch • Colonoscopy every 1–2 years starting at age 20–25 (or 2–5y before earliest family diagnosis); • Prophylactic TAH-BSO at age 40–45; • Upper endoscopy (EGD) q2–4y starting age 35–40
Familial Adenomatous Polyposis (FAP) APC (5q21); Autosomal Dominant Hundreds to thousands of colonic adenomas (100% CRC risk by 40–50y); duodenal ampullary adenomas, desmoid tumors, CHRPE, osteomas • Colonic carpet of >100 adenomatous polyps on endoscopy; • CHRPE on dilated eye exam; • Germline APC gene sequencing • Annual flexible sigmoidoscopy/colonoscopy starting at age 10–12 ; • Prophylactic total proctocolectomy (IPAA) in late teens/early 20s; • Upper endoscopy starting at age 25–30
Hypertrophic Cardiomyopathy (HCM) MYH7, MYBPC3 ; Autosomal Dominant Asymmetric septal hypertrophy, dynamic LVOT obstruction, systolic anterior motion (SAM) of mitral valve, sudden cardiac death in young athletes • Harsh left sternal murmur that increases with Valsalva/standing and decreases with squatting/handgrip ; • Echo: septal thickness ≥15 mm • Cascade genetic testing of first-degree relatives; • Serial clinical screening with 12-lead ECG and TTE every 1–2y in teens (12–18y) and every 3–5y in adults; • Beta-blockers, myectomy, or ICD for high SCD risk
Hereditary Hemochromatosis (HH) HFE (C282Y homozygosity) ; Autosomal Recessive Cirrhosis, hepatocellular carcinoma, "bronze diabetes", hypogonadotropic hypogonadism, cardiomyopathy, 2nd/3rd MCP arthropathy • Fasting Transferrin Saturation ≥45% ; • Elevated ferritin; • Confirmatory HFE C282Y mutation testing • Therapeutic phlebotomy to target ferritin 50–100 mcg/L and TSAT <50%; • Screen for HCC with ultrasound q6m if cirrhosis is present; • Note: Arthropathy does NOT resolve with phlebotomy
The Genetic Information Nondiscrimination Act (GINA) of 2008
The Genetic Information Nondiscrimination Act (GINA) was enacted by the United States Congress to address public fears that predictive genetic testing results could be weaponized by insurers or employers. Understanding the exact statutory boundaries of GINA is a frequent, high-yield topic on the ABFM board examination.
Legal Protections Granted Under GINA
GINA defines "genetic information" expansively to include an individual's genetic test results, the genetic test results of family members, family medical history (up to fourth-degree relatives), and participation in clinical genetic research or genetic counseling. GINA provides robust protections across two specific domains:
Health Insurance Protections (Title I) :
Group health plans, private individual health insurance policies, and Medicare supplemental policies cannot use genetic information to determine eligibility, underwriting, or premium rates.
Health insurers cannot classify genetic information as a pre-existing condition in the absence of manifest, diagnosed disease.
Health insurers are strictly prohibited from demanding, requesting, or requiring that an individual or their family members undergo genetic testing.
Employment Protections (Title II) :
Employers with 15 or more employees , employment agencies, labor organizations, and joint labor-management training programs cannot use genetic information in decisions concerning hiring, firing, job assignments, promotions, layoffs, or compensation.
Employers are prohibited from requesting, requiring, or purchasing genetic information regarding an employee or their family members.
Critical Statutory Limitations & Board Exam Pitfalls
Clinicians must clearly communicate the critical gaps in GINA protections to patients considering predictive genetic testing:
GINA Explicitly Does NOT Apply to Other Insurance Underwriting :
Life Insurance : Life insurance companies CAN legally request genetic test results, consider family history, adjust premiums, or deny life insurance coverage based on pathogenic variants (e.g., BRCA1, Lynch syndrome, Huntington disease).
Disability Insurance : Disability underwriters can legally deny policies or charge higher premiums based on genetic test results.
Long-Term Care Insurance : Long-term care insurance underwriters are exempt from GINA and can use genetic test results during underwriting.
Exempted Employment & Military Populations :
Employers with fewer than 15 employees are exempt from GINA Title II.
Active-Duty Military Personnel (TRICARE) and the military healthcare system are not covered by GINA (governed by internal Department of Defense regulations).
The Veterans Health Administration (VHA), Indian Health Service (IHS), and Federal Employees Health Benefits Program (FEHB) are exempt from GINA, though separate executive orders provide parallel protections for federal civilian employees.
Manifest Symptomatic Illness vs. Asymptomatic Genetic Predisposition :
GINA protects against discrimination based on predictive genetic predisposition or family history in an asymptomatic individual.
Critical Distinction : Once an individual develops clinically manifest, diagnosed, symptomatic disease (e.g., a patient carrying BRCA1 who is diagnosed with invasive breast cancer, or a patient with HFE C282Y who has biopsy-proven cirrhosis), GINA no longer applies to the clinical diagnosis. Patient protections against health insurance discrimination based on active, manifest pre-existing conditions fall under the Affordable Care Act (ACA) , and workplace disability accommodations fall under the Americans with Disabilities Act (ADA) .